Patents by Inventor PAMELA A. PAVCO

PAMELA A. PAVCO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
    Publication number: 20030125270
    Abstract: Enzymatic nucleic acid molecules (e.g., ribozymes and DNAzymes) that modulate the expression and/or replication of hepatitis C virus (HCV).
    Type: Application
    Filed: December 18, 2000
    Publication date: July 3, 2003
    Inventors: Lawrence Blatt, James McSwiggen, Elisabeth Roberts, Pamela A. Pavco, Dennis Macejack
  • Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
    Patent number: 6566127
    Abstract: The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 20, 2003
    Assignees: Ribozyme Pharmaceuticals, Inc., Chiron Corporation
    Inventors: Pamela Pavco, James A. McSwiggen, Dan T. Stinchcomb, Jaime Escobedo
  • ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO HEPATITIS C VIRUS INFECTION
    Publication number: 20020082225
    Abstract: Enzymatic nucleic acid molecules which modulate the expression and/or replication of hepatitis C.
    Type: Application
    Filed: March 23, 1999
    Publication date: June 27, 2002
    Inventors: LAWRENCE BLATT, JAMES A. MCSWIGGEN, BETH ROBERTS, PAMELA A. PAVCO, DENNIS MACEJACK
  • Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
    Patent number: 6346398
    Abstract: Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: February 12, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Pamela Pavco, James McSwiggen, Daniel Stinchcomb, Jaime Escobedo
  • Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them
    Patent number: 6214621
    Abstract: The invention relates to an ionic conjugate, which is stable in a biological medium, and which is comprised of a particle vector with at least one cationic, nonliquid, hydrophilic nucleus and of polyanionic oligonucleotides. The invention further concerns the pharmaceutical compositions containing these conjugates and the use of a particle vector to carry the oligonucleotides to the cells.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: April 10, 2001
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Roger Kravtzoff, Ignacio de Miguel, Sophie Sixou, Pamela Pavco, Thale Jarvis
  • Method of reducing stromelysin RNA via ribozymes
    Patent number: 5731295
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of an arthritic condition.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: March 24, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Pamela Pavco, James McSwiggen, John Gustofson, Dan T. Stinchcomb
  • Stromelysin targeted ribozymes
    Patent number: 5612215
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of an arthritic condition.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: March 18, 1997
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Pamela Pavco, James McSwiggen, John Gustofson, Dan T. Stinchcomb